N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxamide

ID: ALA4742132

PubChem CID: 162647311

Max Phase: Preclinical

Molecular Formula: C18H22N4O3S

Molecular Weight: 374.47

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CC=CCC3)nc12

Standard InChI:  InChI=1S/C18H22N4O3S/c1-24-14-6-5-13(21-9-11-25-12-10-21)16-15(14)19-17(26-16)20-18(23)22-7-3-2-4-8-22/h2-3,5-6H,4,7-12H2,1H3,(H,19,20,23)

Standard InChI Key:  SJFBTOOXZLJLKA-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
    7.2790   -3.8094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2779   -4.6289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9859   -5.0379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9841   -3.4005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6927   -3.8058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6930   -4.6290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4760   -4.8831    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.9597   -4.2170    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4756   -3.5512    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    7.9812   -2.5835    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6888   -2.1729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6879   -1.3594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9807   -0.9496    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.2728   -1.3594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2721   -2.1790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9838   -5.8537    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.2751   -6.2605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7761   -4.2195    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.1868   -3.5130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0040   -3.5155    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.7804   -2.8041    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.1908   -2.0932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7878   -1.3864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9703   -1.3797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5574   -2.0860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9620   -2.7990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9  5  1  0
  4 10  1  0
 10 11  1  0
 10 15  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
  3 16  1  0
 16 17  1  0
  8 18  1  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 21 26  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4742132

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 374.47

Molecular Weight (Monoisotopic): 374.1413

AlogP: 2.94

#Rotatable Bonds: 3

Polar Surface Area: 66.93

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 7.96

CX Basic pKa: 0.13

CX LogP: 2.53

CX LogD: 2.42

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.84

Np Likeness Score: -1.64

References

1. Renk DR,Skraban M,Bier D,Schulze A,Wabbals E,Wedekind F,Neumaier F,Neumaier B,Holschbach M.  (2021)  Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A receptor ligands.,  214  [PMID:33548636] [10.1016/j.ejmech.2021.113214]

2. Saini A, Patel R, Gaba S, Singh G, Gupta GD, Monga V..  (2022)  Adenosine receptor antagonists: Recent advances and therapeutic perspective.,  227  [PMID:34695776] [10.1016/j.ejmech.2021.113907]

Source

Source(1):

• Scientific Literature